WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, today announced that it has acquired Geospiza, Inc., a leading developer of software systems for the management of genetic analysis and laboratory workflows delivered through a Web-based secure cloud computing environment.
The acquisition of Geospiza supports PerkinElmer’s growing offerings in Next Generation DNA Sequencing and Analysis Services, which enable researchers to explore the genomic origins of disease more effectively, and help address customers’ growing need to manage knowledge and drive scientific productivity. The addition of Geospiza to PerkinElmer’s sequencing and analysis services will deliver an end-to-end solution that provides scientists access to sequencing services and robust analysis and visualization software, offered through significant capability around cloud computing. This solution enables “anytime, anywhere” genomic data interpretation and analysis, all backed by PerkinElmer expertise and the highest quality standards.
“Genomic information is becoming increasingly important in understanding and treating disease. Making sense of the unprecedented volumes of data generated by next generation sequencing and other biological measurements is critical to improve the disease diagnosis process and drug discovery,” said Richard Begley, PhD, president, Emerging Technologies, PerkinElmer.
He added, “The acquisition of Geospiza, along with existing software in our various diagnostic businesses, gives PerkinElmer a strong platform for offerings in nucleic acid testing. Geospiza is a leader in its industry, and a strong addition to PerkinElmer’s bioinformatics capabilities. We look forward to expanding our family of genetic analysis offerings in research, drug discovery and diagnostics.”
Geospiza’s clients include biotechnology and pharmaceutical companies, universities, researchers, contract core and diagnostic service laboratories involved in genetic testing and manufacturing biotherapeutics.
Geospiza’s current informatics offerings include:
- GeneSifter™ Analysis Edition – a cloud-based data analysis product for microarray and next generation sequencing data. GeneSifter Analysis Edition helps biologists readily incorporate sophisticated data management and computational analysis into their research efforts. The results include improved quality and productivity in the experimental and decision-making processes. This product is a valuable tool for interpreting the vast amounts of genetic data produced by Microarray and Next Generation Sequencing technologies and supports all of the major sequencing and array platforms.
- GeneSifter™ Lab Edition – Geospiza’s software platform supporting laboratory workflows. This out-of-the-box lab management system with intelligent workflows helps researchers get started immediately, and has flexibility to adapt to specific needs without custom programming. Genesifter Lab Edition significantly increases capacity, reduces backlog, eliminates errors due to manual processes, and speeds time to discovery in user labs.
Factors Affecting Future Performance
This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities and divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products declining or not growing as anticipated; (2) fluctuations in the global economic and political environments; (3) our failure to introduce new products in a timely manner; (4) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable, or successfully divest businesses; (5) our failure to adequately protect our intellectual property; (6) the loss of any of our licenses or licensed rights; (7) our ability to compete effectively; (8) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (9) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (10) disruptions in the supply of raw materials and supplies; (11) the manufacture and sale of products exposing us to product liability claims; (12) our failure to maintain compliance with applicable government regulations; (13) regulatory changes; (14) our failure to comply with healthcare industry regulations; (15) economic, political and other risks associated with foreign operations; (16) our ability to retain key personnel; (17) significant disruption in our information technology systems; (18) restrictions in our credit agreements; (19) our ability to realize the full value of our intangible assets; (20) significant fluctuations in our stock price; (21) reduction or elimination of dividends on our common stock; and (22) other factors which we describe under the caption "Risk Factors" in our most recent annual report on Form 10-K and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
About Geospiza, Inc.
Designed by biologists for biologists, Geospiza is the developer of GeneSifter® software, providing integrated solutions for Next Generation Sequencing analysis and LIMS. For over 10 years, Geospiza has set the industry standard for high value, low cost, “out of the box” solutions serving the life sciences market. You can find more information on Geospiza and its products at www.geospiza.com.
About PerkinElmer, Inc.
PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of approximately $1.7 billion in 2010, has about 6,200 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.